Our vision for the future is to continue to be a successful and profitable company, which also has launched its own desirable specialist pharmaceuticals internationally.
We have the strength and expertise to develop innovative products that offer substantial patient value. The company has extensive research experience within proteins. Currently we have several unique specialist care projects in our pipeline. We also have validated production units and marketing capabilities, thus completing the whole value chain from research and production to the patient.
Our research and development focuses primarily on new drugs for the treatment of blood diseases, autoimmune diseases/inflammation and malabsorption. We endeavor to maintain our world-class standing in these areas and our strategy is to retain the rights and pursuit of development programs in-house all the way to the market.
We currently market a number of specialist-prescribed drugs internationally. Our ambition is to continue to increase our product range and broaden our markets.
We produce proteins both for our own projects as well as together with other companies. Our production meets the global need for the active ingredient in ReFacto AF® (Xyntha®). We also manufacture research material for all phases of clinical studies. Since the characteristics of different proteins vary significantly and thereby place different demands on the production process, flexibility within the organization and production facilities is required, as is a high level of expertise among employees.
Our corporate culture combines science with commercial performance and is based on commitment, new mindsets, accountability and focus on results.
